{"filing":{"accession_number":"0001213900-26-068483","cik":"0001084201","ticker":"SVA","company_name":"SINOVAC BIOTECH LTD","form":"6-K","filing_date":"2026-06-15","report_date":null,"primary_document":"ea0294745-6k_sinovac.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1084201/000121390026068483/ea0294745-6k_sinovac.htm"},"events":[{"id":12248,"run_id":10812,"accession_number":"0001213900-26-068483","anchor_item_number":"EX-99.1","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"summary":"The press release announces that Sinovac \"regained compliance with Nasdaq Global Market's listing requirements\" after receiving a notification letter dated June 10, 2026, from the Nasdaq Hearing Advisor. This disclosure directly addresses a prior delisting risk or non-compliance status. The company remains under \"Mandatory Panel Monitor\" until May 20, 2027, indicating it was previously out of compliance with Listing Rule 5250(c)(1). This is a material event affecting the registrant's continued listing status on Nasdaq.","company_name":"SINOVAC BIOTECH LTD","ticker":"SVA","filing_date":"2026-06-15","form":"6-K","submitted_at":null,"items":[{"id":9051,"accession_number":"0001213900-26-068483","item_number":"EX-99.1","item_title":"ea029474501ex99-1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The press release announces that Sinovac \"regained compliance with Nasdaq Global Market's listing requirements\" after receiving a notification letter dated June 10, 2026, from the Nasdaq Hearing Advisor. This disclosure directly addresses a prior delisting risk or non-compliance status. The company remains under \"Mandatory Panel Monitor\" until May 20, 2027, indicating it was previously out of compliance with Listing Rule 5250(c)(1). This is a material event affecting the registrant's continued listing status on Nasdaq.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:30:50.666995+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9051,"accession_number":"0001213900-26-068483","item_number":"EX-99.1","item_title":"ea029474501ex99-1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The press release announces that Sinovac \"regained compliance with Nasdaq Global Market's listing requirements\" after receiving a notification letter dated June 10, 2026, from the Nasdaq Hearing Advisor. This disclosure directly addresses a prior delisting risk or non-compliance status. The company remains under \"Mandatory Panel Monitor\" until May 20, 2027, indicating it was previously out of compliance with Listing Rule 5250(c)(1). This is a material event affecting the registrant's continued listing status on Nasdaq.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T02:30:50.666995+00:00","company_name":"SINOVAC BIOTECH LTD","ticker":"SVA","filing_date":"2026-06-15"}]}